BioTuesdays

Tag - VKTX

Viking Therapeutics Logo
Markets

WB starts Viking Therapeutics at OP

William Blair launched coverage of Viking Therapeutics (NASDAQ:VKTX) with an “outperform” rating. The stock closed at $3.97 on April 27. Viking has a differentiated clinical pipeline focusing on modulating hormone...

April 30, 2018
Feature

Viking Therapeutics to complete two POC trials in 2016

By Len Zehr Viking has successfully completed three Phase 1 studies with VK5211, including a 21-day ascending dose study. Viking Therapeutics (NASDAQ:VKTX) expects to complete two proof-of-concept Phase 2 trials in 2016...

November 10, 2015